-
Bayer's Nubeqa is supported by NICE for the treatment of prostate cancer
Time of Update: 2020-11-05
about a third of men with non-metastatic desopathic prostate cancer (nmCRPC) underscore the medical needs of these patients within two years.
,000-year-old Nubeqa is supported by the National Institute for Health and Care Excellence (NICE) in the UK in the treatment of non-metastatic desopathic prostate cancer (nmCRPC).
-
Clin Cancer Res: HR-HER2 - Brain metastasis breast cancer patients benefit the most from Abemaciclib treatment
Time of Update: 2020-11-05
study process was designed to assess intracranial objective remission rates (iORRs) in patients with secondary LM who were treated with Abemaciclib, as well as to assess extracranial response, Abemaciclib pharmacodynamics, brain metastasis tissue exposure and safety.
-
Cell Death Dis:lncRNA CASC9: Triggers of gyfygenic resistance in non-small cell lung cancer
Time of Update: 2020-11-05
CASC9 regulation in NSCLC Gifetinib resistance schematic mechanism study found that CASC9 can inhibit the tumor inhibitor DUSP1 by collecting histone methyl metastase EZH2, and ultimately improve the resistance of gyfrotein.
-
Caring for Women's Health iCare Breast Public Interest Program is in action
Time of Update: 2020-11-05
Professor Lu Ping, Director of the Women's and Children's Health Hospital of Biji City, Guizhou Province, also congratulated the project in his speech: Breast cancer prevention and treatment is related to the health of every woman, self-confidence and the future, more social forces are significantly improving the level of primary health care and the concept of diagnosis and treatment, from the top medical institutions of medical experience and industry-leading enterprises of technical support for primary medical institutions is very valuable.
-
ACG 2020: Vedolizumab significantly improves immunotherapy-related diarrhea compared to Invlizumab
Time of Update: 2020-11-05
"Our first large-scale study showed that Vedolizumab had the same effect on the clinical remission of immunotherapy-mediated diarrhea and colitis compared to Invlizumab, but patients had significantly shorter courses and lower recurrence rates," said Dr. Yinghong Wang of the University of Texas Anderson Cancer Center.
-
Roche Taishengqi® immune combination therapy program approved in China for the treatment of hepatocellular carcinoma
Time of Update: 2020-11-05
On October 28, 2020, Roche announced that China's State Drug Administration (NMPA) had approved its cancer immuno-innovative drug Atiliju monoanti (trade name: Tai Sanqi ®, Tecentriq®) to treat patients with non-excisible hepatocellular carcinoma (HCC) who had not previously received systematic treatment.
-
Cell Death Differ:CHIP mediates CIP1 ubiturization to regulate the epitheline-interstitine transformation process and tumor metastasis of lung adenocarcinoma
Time of Update: 2020-11-05
the ability of LAC to reduce CIP1-induced LAC migration and metastasis by raising CHIP expression was found to have an increase in the expression level of CIP1 in LAC tissue and cell line, and was associated with clinical pathological characteristics and adverse prognosis in patients.
-
Huang Bin: Experience in the treatment of ruptured abdominal aortic aneurysms
Time of Update: 2020-11-05
meta-analysis published in 2017: 761 RAAA patients in four randomized controlled studies showed no statistically significant statistical differences in mortality and postoperative complications over 30 days of hospitalization in the EVAR and OR groups.
-
PD-L1 monoantial Tecentriq and VEGF monoantial Avastin: Approved to treat the most common liver cancer patients in China
Time of Update: 2020-11-05
The approval was based on the results of the Phase III IMbrave150 study, which showed that Tecentriq and Avastin reduced the risk of death (overall survival rate, OS) by 56 percent and the risk of disease deterioration or death (no progression, PFS) by 40 percent compared to Sorafini.
-
KraS inhibitor adagrasib treated non-small cell lung cancer with no disease progression in 83% of the responding patients
Time of Update: 2020-11-05
83% of NSCLC respondents had no progression I/Ib and Phase II studies that included 51 patients with advanced NSCLC who received a median of two systemic treatments, all of which had received platinum-based chemotherapy, and 92% of patients who had previously received anti-PD-1/L1 inhibitors.
-
Inventory: A selection of Lancet studies dated October 31, 2020
Time of Update: 2020-11-05
1. The effect of assisted radiotherapy on event-free survival in prostate cancer patients immediately after root-based surgery DOI: https://doi.org/10.1016/S0140-6736 (20)31952-8 Recently, researchers conducted a randomized controlled study to compare the effects of ancillary radiotherapy or early remedial radiotherapy on local or late prostate cancer patients after a root-based prostateectomy.
-
Henan Cancer Hospital and Baiji Shenzhou strategic cooperation, complementary resources to improve the level of cancer diagnosis and treatment
Time of Update: 2020-11-04
Wu Xiaobin, president of Baiji Shenzhou Company, said that Henan Cancer Hospital has outstanding medical and clinical research capabilities, and looks forward to working together to contribute to the development of China's new drug creation through in-depth cooperation between the two sides, bringing hope to more patients and bringing more "China programs" to the world.
-
Oriental Hospital cooperates with Yancheng Zhong Hospital in the construction of oncology specialty
Time of Update: 2020-11-04
Tu/Yu Jiankun meeting around the Beijing-Tianjin-Hebei Chinese medicine collaborative development project construction, project implementation, budget implementation, fund allocation, capacity improvement and other aspects of the task objectives and work assignment, in order to help Hebei Province project units to solve a medical urgent need, break through a weak link, bring out a technical team, a new service project cooperation objectives, effectively meet the needs of the vast number of people in the region for Chinese medicine services.
-
"Internet plus medical" into a new trend, Tianjin Cancer Hospital Internet Hospital online trial operation
Time of Update: 2020-11-04
Under the new era of rapid development of information technology, the integration and development of "Internet plus medical care" has become a new trend. October 29, the National Cancer Specialist Al
-
"White Paper on Nutritional Diet for Chinese Cancer Patients (2020-2021)" released in Beijing
Time of Update: 2020-11-04
"Families, businesses, patient organizations and governments need to work together to promote scientific nutrition management, address malnutrition in patients, and improve the prevention, treatment a
-
Cell: New cancer immunotherapy based on nanobiology may be expected to cure cancer once and for all
Time of Update: 2020-11-04
November 3, 2020 // -- In a recent study published in the international journal Cell, scientists from Mount Sinai Hospital and other institutions made significant progress in the development of new cancer immunotherapy by pairing nano-bio-micromaterials with therapeutic ingredients produced by bioengineering natural molecules and then training the body's congenital immune system to destroy tumor cells.
-
Radioactive particle implantation: treatment of recurring incurable tumors
Time of Update: 2020-11-04
Some patients with recurring and incurable tumors, often can no longer undergo surgery or radiotherapy, in this case, you can try 3D printing templates to assist CT to guide radioactive particle technology to diagnosis and treatment.
-
Esophageal Cancer (ESCC) immunotherapy! Best-in-a-lifetime Opdivo (Odivo) is recommended for approval by CHMP in the European Union: second-line treatment significantly extends survival!
Time of Update: 2020-11-02
October 17, 2020 // -- BMS recently announced that the European Medicines Agency (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued a positive review recommending approval of anti-P D-1 therapy Opdivo (Odivo, generic name: nivolumab, Navuliyu monoanti) A new adaptive disorder used to treat adult patients with non-excisive, late, relapsed or metastatic esophageal squamous cell carcinoma (ESCC) who previously underwent a combination of fluorine and platinum-based chemotherapy.
-
Lung cancer is heavy! Long-term follow-up to the first-line treatment of Keytruda and chemotherapy in Meshadon: complete 2 years of Keytruda treatment of patients with a 3-year survival rate of 92%!
Time of Update: 2020-11-02
October 19, 2020 // -- Merck Co) recently announced positive results for two clinical studies of the anti-PD-1 therapy Keytruda (Corida, generic name: pembrolizumab, Pabliju monoanti) lung cancer clin
-
Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx program was reviewed by the FDA as a priority, beating Sutt!
Time of Update: 2020-11-01
data show that in patients with advanced RCC who had not previously been treated, the first-line standard care drug Suttent (Sotan, generic name: sunitinib, schoinistinib, a tyrosine kinase inhibitor, developed by Pfizer) In contrast, the "Immune plus Target" scheme Opdivo-Cabometyx showed significant improvements at all ends of the efficacy, including total lifetime (OS), progress-free lifetime (PFS), objective mitigation rate (ORR), and mitigation duration (DOR).
